CASI Pharmaceuticals Announces First Quarter 2018 Financial And Business Results
First Quarter and Recent Business Highlights
Company prepares for commercial launch of EVOMELA® in
Update on advisory committee meeting notice from
Acquired portfolio of 25
Announced
Upcoming presentations - CASI will provide a corporate update at the 2018
Financial Results for the Quarter ended
Cash Position: As of
R&D Expenses: R&D expenses for the quarter ended March 31, 2018 were $1.7 million compared to
G&A Expenses: G&A expenses for the quarter ended March 31, 2018 were $1.3 million compared to
Net Loss: The Company reported a net loss of (
Further information regarding the Company, including its Quarterly Report on Form 10-Q for the quarter ended
About
Forward Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: risks relating to interests of our largest stockholders that differ from our other stockholders; the difficulty of executing our business strategy in
EVOMELA® is proprietary to Spectrum Pharmaceuticals, Inc. and its affiliates.
Herceptin® and Xeloda® are proprietary to
COMPANY CONTACT: |
INVESTOR CONTACT: |
MEDIA CONTACT: |
|
Solebury Trout |
|
240.864.2643 |
|
|
646.378.2962 |
410.299.3310 |
|
|
||
617 221 9005 |
||
(Financial Table Follows)
|
|||
SUMMARY OF OPERATING RESULTS |
|||
Three Months Ended |
|||
2018 |
2017 |
||
Total Revenues |
$ - |
$ - |
|
Research & development |
|
|
|
General & administrative |
|
$ 644,163 |
|
Acquired in-process research and development |
$ 686,998 |
$ - |
|
Net loss |
|
|
|
Net loss per share attributable to common shareholders |
$ (0.05) |
$ (0.03) |
|
Weight average number of shares outstanding (basic and |
71,215,000 |
60,196,574 |
|
Cash and cash equivalents |
|
|
View original content with multimedia:http://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-first-quarter-2018-financial-and-business-results-300648138.html
SOURCE
Five Star Senior Living Inc. Announces First Quarter 2018 Results
First Congressional District Democratic primary candidates want Trump impeached
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News